Oligonucleotide Manufacturing Facility Design

Oligonucleotide Manufacturing Facility Design

Agilent Technologies Inc. recently completed a production facility in Colorado that more than doubles its capacity to develop and manufacture “oligos,” which are short DNA and RNA molecules that customers use to produce nucleic acid-based therapeutics. CRB performed engineering design and architecture of the new state-of-the-art facility in Frederick, about 30 miles north of Denver. It produces oligonucleotide (“oligo”) active pharmaceutical ingredients, which hold the potential to treat cancer, rare and infectious diseases, cardiovascular indications, and other disorders.

The $185 million facility in Frederick covers 135,000 square feet. It also expands Agilent’s presence in Colorado, where the company has had an oligo manufacturing site in nearby Boulder since 2006. Both sites are current Good Manufacturing Practices (CGMP) facilities, as designated by the U.S. Food and Drug Administration.

Project Details


Agilent Technologies Inc.


Frederick, CO

Square Footage



$185 million

 Return to top